ANGLE’s Parsortix System Demonstrates Notable Performance in the Capture of Circulating Tumor Cells Versus Other Separation...
January 25 2016 - 6:00AM
Business Wire
New research, to be published in the
International Journal of Cancer, shows the ParsortixTM
System efficiently captures and harvests intact, viable
circulating tumor cells (CTCs) to allow for broader downstream CTC
analysis
A rigorous evaluation by researchers at University Medical
Centre Hamburg-Eppendorf (UKE) published in the International
Journal of Cancer today of ANGLE’s ParsortixTM cell separation
system demonstrated significant advantages of its size and
deformability based enrichment technology, versus marker-based and
filtration enrichment systems.
The report, A Novel Microfluidic Platform for Size and
Deformability Based Separation and the Subsequent Molecular
Characterization of Viable Circulating Tumor Cells, determined that
the ParsortixTM System enables the isolation of viable CTCs at a
very high purity and provides viable tumor cells that are easily
accessible and ready for a broad range of molecular and functional
analyses. “The system’s ability to provide numeration and molecular
characterization of EpCAM-negative CTCs will help to broaden
research into the mechanisms of cancer as well as facilitating the
use of CTCs in ‘liquid biopsies,’” the report stated.
According to co-author Prof. Klaus Pantel, Chairman, Department
of Tumor Biology at UKE’s Centre of Experimental Medicine, systems
that can comprehensively capture the broad range of CTCs – not only
epithelial cells, but others including mesenchymal cells – will
play an important role in cancer diagnoses and subsequent
treatment.
“Our findings emphasize the importance of developing new
label-free assays that allow the molecular characterization of CTCs
for therapeutic targets and resistance mechanisms at the DNA, RNA
and protein level,” Pantel said. “This information is vital as
liquid biopsies will help clinicians to adapt therapies to the
individual needs of cancer patients.”
To put ParsortixTM through its paces, the team of researchers
lead by Prof. Pantel, working from three locations in Philadelphia,
Hamburg and Dusseldorf analyzed the performance of the
marker-independent system for the capture of tumor cells from blood
samples spiked with five different cancer cell lines and multiple
patient samples including metastatic breast, non-metastatic colon,
metastatic colon, metastatic lung, and non-metastatic lung cancer.
Using the system, UKE researchers showed average tumor cell capture
ranged from 42 per cent to 70 per cent with subsequent harvest of
the cells ranging between 54 per cent and 69 per cent of the cells
captured. One of the novel and powerful capabilities that
distinguishes the ParsortixTM system is that it enables easy
harvest of captured tumor cells for further downstream analyses. In
addition, 99 per cent of the harvested CTCs from both spiked and
patient samples were viable after processing and still functional
for downstream molecular analysis as demonstrated by mRNA
characterization and array based comparative genomic
hybridization.
“The epitope independent ParsortixTM system enables the
isolation of viable CTCs at a very high purity. Using our system,
viable tumor cells are easily accessible and ready for molecular
and functional analysis,” said Dr George Hvichia, the inventor of
ParsortixTM technology and CSO, ANGLE plc. “The system’s ability
for enumeration and molecular characterization of EpCAM-negative
CTCs will help to broaden research into the mechanisms of cancer as
well as facilitating the use of CTCs as liquid biopsies.”
The results obtained by the collaborative team demonstrate the
importance of being able to effectively harvest CTCs not only with
epithelial characteristics, but also those in the process of, or
that have completed, epithelial-to-mesenchymal transition (EMT)
across a broad range of cancer types.
A growing body of evidence has shown that cancer cells in the
process of, or that had completed EMT have increased invasion
capabilities, which leads to the loss of epithelial cell adhesion
molecule (EpCAM) antibodies. Currently, CTC isolation is still
mainly based on EpCAM expression on the surface of cancer cells of
epithelial origin. New research, however, indicates that EMT is
increasingly recognized to play a significant role in metastasis
and certain EMT cancer cells lose EpCAM expression. Isolation by
techniques that are independent of marker expression, such as
ParsortixTM, may help to capture those EMT CTCs and provide a more
precise path to the diagnosis and treatment of metastatic
cancer.
About ANGLE plc
ANGLE is a UK-based specialist medtech company commercializing
the ParsortixTM system, a cell separation technology that enables a
simple blood test to harvest targeted cells, such as circulating
tumor cells (CTCs) for molecular profiling and analysis.
ParsortixTM can help deliver targeted cancer diagnostics designed
to inform personalized treatment of cancer. It is also designed to
be compatible with existing major medtech analytical platforms and
enable companion diagnostics for major pharma in helping to
identify patients that will benefit from a particular drug and then
monitoring the drug’s effectiveness. ANGLE has established formal
collaborations with world-class cancer centers and is working with
these cancer centers to demonstrate key applications for its
ParsortixTM non-invasive cancer diagnostic system as a liquid
biopsy. In addition to cancer cells, the ParsortixTM technology has
the potential for deployment for other clinically significant cell
types in the future.
ANGLE’s ParsortixTM system is available for research use
worldwide and is CE-IVDD Marked for indicated clinical use in
Europe.
ANGLE is a public company trading on the AIM market of the
London Stock Exchange under the ticker symbol AGL and in the United
States on the OTC-QX market under the ticker symbol ANPCY.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160125005287/en/
ANGLE plcPeggy Robinson, 914-525-5928Vice PresidentorBrandwidth
Solutions LLCChris Anderson,
207-232-7007canderson@brandwidthsolutions.com
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024